Add to a list

Inactive Instrument

Findit, Inc. Stock Other OTC

FDIT

US31772N1000

Medical Equipment, Supplies & Distribution

OTC Markets Traded

BioRegenx, Inc. operates as a holding company specializing in acquiring intellectual property (IP) and companies engaged in regenerative biotherapeutics and anti-aging research. The Companyâ€™s subsidiaries include DocSun BioMedical Holdings, Inc. (DocSun), Microvascular Health Solutions, LLC (MVHS), MyBodyRx, LLC (MyBodyRx), NuLife Sciences, Inc. (NuLife) and Findit Ai Connect, Inc. (Findit Ai). DocSun combines three technologies in the DocSun Artificial Intelligence (AI) Engine. The DocSun AI Engine integrates advanced ballistocardiography, which can detect an individual's heartbeat without touch, and photoplethysmography, a method that uses light to track the flow of blood. MVHS specializes in research, product development, sales, and education, notably producing the patented Endocalyx Pro dietary supplement. MVHS also manufactures and distributes the patented GlycoCheck software and Class 1 medical devices. DocSun is also developing an app for NuLife, TruScan.Ai mobile app/Website.

Employees

Sector

Medical Equipment, Supplies & Distribution

More about the company

The best tools reserved for subscribers to boost the performance of your investments!

Market Cap	5.3M 4.65M 4.39M 4M 7.49M 507M 7.55M 52.59M 20.34M 259M 19.88M 19.45M 834M	P/E 2024	-0.37x	P/E 2025	-8.02x
Enterprise Value	7.44M 6.54M 6.17M 5.62M 10.53M 713M 10.61M 73.89M 28.58M 364M 27.93M 27.33M 1.17B	EV / Sales 2024	4.58x	EV / Sales 2025	7.85x
Free-Float	25.48%	Yield 2024 *	-	Yield 2025	-

21/05	BioRegenx, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
16/04	BioRegenx, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
15/04	BioRegenx, Inc. Auditor Raises 'Going Concern' Doubt	CI
15/11	BioRegenx, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
15/08/25	BioRegenx, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
16/05/25	BioRegenx, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
16/04/25	BioRegenx, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
15/04/25	BioRegenx, Inc. Auditor Raises 'Going Concern' Doubt	CI
15/04/25	BioRegenx, Inc. Announces Board Resignations	CI
23/01/25	BioRegenx, Inc. Announces the Resignation of Robert Doran as Director	CI
15/11/24	BioRegenx, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	CI
12/10/24	BioRegenx, Inc. Announces Board Changes	CI
10/10/24	BioRegenx, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	CI

10/12	BioRegenx, Inc. (OTC: BRGX) Announces Major Corporate Progress, Auditor Transition, Technology Integration, and AI-Driven Strategic Vision	GL
01/01/25	OneView Commerce Expands Omnichannel Store Fulfillment Leadership with Batch Picking, Omni Returns and FindIt	AQ
10/10/24	BioRegenx : Quarterly Report for Quarter Ending June 30, 2024 (Form 10-Q)	PU
10/10/24	BioRegenx : Amendment to Current Report Form 8 K/A	PU
11/06/24	BioRegenx : Non Reliance on Previously Issued Financial Report Form 8 K	PU

Manager	Title	Age	Since
William Resides CEO	Chief Executive Officer	57	08/03/2024
Gary Hennerberg SEC	Corporate Secretary	69	08/03/2024

Director	Title	Age	Since
Thomas Powers BRD	Director/Board Member	71	01/01/2012
William Resides BRD	Director/Board Member	57	08/03/2024
Suzanne Bird BRD	Director/Board Member	61	08/03/2024

Findit, Inc. Stock Other OTC

Stocks

FDIT

US31772N1000

Medical Equipment, Supplies & Distribution

Valuation: Findit, Inc.

Latest news: Findit, Inc.

Press Releases: Findit, Inc.

Quotes and Performance

Managers and Directors: Findit, Inc.

Other Medical Equipment, Supplies & Distribution

Financials

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
FINDIT, INC.	-7.28%	+11.68%	-	-	5.3M
ABBOTT LABORATORIES	+0.22%	-1.29%	-24.16%	+6.03%	175B
MEDTRONIC PLC	+0.97%	-3.79%	-5.92%	+13.32%	113B
CENCORA, INC.	-0.95%	-0.60%	-0.03%	+65.76%	58.57B
BECTON, DICKINSON AND COMPANY	+2.56%	+1.59%	-0.42%	-28.97%	50.07B
HOYA CORPORATION	+1.49%	+3.89%	+15.12%	+53.65%	49.92B
DEXCOM, INC.	-0.97%	-3.06%	+29.09%	-5.94%	32.69B
MEDLINE INC.	+0.12%	+9.67%	-	-	30.44B
WEST PHARMACEUTICAL SERVICES, INC.	-0.85%	+2.24%	+41.65%	-1.26%	26.07B
SARTORIUS STEDIM BIOTECH	-1.58%	+7.22%	+23.81%	-4.32%	23.55B
Average	-0.63%	+1.73%	+9.89%	+12.28%	62.22B
Weighted average by Cap.	+0.37%	-0.01%	-2.98%	+13.82%

	2024	2025
Net sales	2.34M 2.06M 1.94M 1.77M 3.31M 224M 3.34M 23.24M 8.99M 115M 8.79M 8.59M 369M	1.85M 1.63M 1.54M 1.4M 2.62M 178M 2.64M 18.42M 7.12M 90.78M 6.96M 6.81M 292M
Net income	-23.05M -20.26M -19.12M -17.43M -32.62M -2.21B -32.88M -229M -88.56M -1.13B -86.55M -84.67M -3.63B	-1.54M -1.36M -1.28M -1.17M -2.18M -148M -2.2M -15.33M -5.93M -75.56M -5.8M -5.67M -243M
Net Debt	2.11M 1.85M 1.75M 1.59M 2.98M 202M 3M 20.91M 8.09M 103M 7.91M 7.73M 332M	2.15M 1.89M 1.78M 1.62M 3.04M 206M 3.06M 21.3M 8.24M 105M 8.05M 7.88M 338M